Ftse Mib
34.707,02
1,07%
DAX
18.803,00
0,66%
S&P 500
5.214,08
0,51%
NASDAQ
16.346,26
0,00%
Bitcoin
63.123,72
0,12%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Albireo Pharma Inc (ALBO) Albireo Pharma Inc (ALBO) Notizie

ALBO

Albireo Pharma (ALBO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALBO
DataOraFonteTitoloSimboloCompagnia
14/02/202414:33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALBOAlbireo Pharma Inc
09/03/202312:14Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ALBOAlbireo Pharma Inc
03/03/202312:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202322:53Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202322:49Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202322:32Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202322:29Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202317:29Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:ALBOAlbireo Pharma Inc
02/03/202317:24Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:ALBOAlbireo Pharma Inc
27/02/202322:06Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ALBOAlbireo Pharma Inc
14/02/202322:01Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ALBOAlbireo Pharma Inc
14/02/202314:30GlobeNewswire Inc.FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille SyndromeNASDAQ:ALBOAlbireo Pharma Inc
27/01/202323:29Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:ALBOAlbireo Pharma Inc
23/01/202314:13Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:ALBOAlbireo Pharma Inc
19/01/202322:12Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:ALBOAlbireo Pharma Inc
10/01/202312:07Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:ALBOAlbireo Pharma Inc
21/12/202222:06Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ALBOAlbireo Pharma Inc
20/12/202222:30GlobeNewswire Inc.Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ALBOAlbireo Pharma Inc
19/12/202214:30GlobeNewswire Inc.Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMANASDAQ:ALBOAlbireo Pharma Inc
08/12/202218:35TipRanksWedbush Reaffirms Their Buy Rating on Albireo Pharma (ALBO)NASDAQ:ALBOAlbireo Pharma Inc
06/12/202214:30GlobeNewswire Inc.Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of DirectorsNASDAQ:ALBOAlbireo Pharma Inc
09/11/202214:30GlobeNewswire Inc.Albireo to Participate in Jefferies London Healthcare ConferenceNASDAQ:ALBOAlbireo Pharma Inc
09/11/202212:46TipRanksWedbush Remains a Buy on Albireo Pharma (ALBO)NASDAQ:ALBOAlbireo Pharma Inc
09/11/202212:35TipRanksH.C. Wainwright Remains a Buy on Albireo Pharma (ALBO)NASDAQ:ALBOAlbireo Pharma Inc
08/11/202222:33Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ALBOAlbireo Pharma Inc
08/11/202222:01GlobeNewswire Inc.Albireo Reports Q3 2022 Financial Results and Business UpdateNASDAQ:ALBOAlbireo Pharma Inc
07/11/202214:30GlobeNewswire Inc.Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC TypesNASDAQ:ALBOAlbireo Pharma Inc
03/11/202213:30GlobeNewswire Inc.Albireo Announces 2022 SPARK Grant WinnersNASDAQ:ALBOAlbireo Pharma Inc
02/11/202213:30GlobeNewswire Inc.Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary AtresiaNASDAQ:ALBOAlbireo Pharma Inc
01/11/202213:30GlobeNewswire Inc.Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022NASDAQ:ALBOAlbireo Pharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALBO

La tua Cronologia

BIT
ENEL
Enel
BIT
UCG
Unicredit
BIT
BFF
BFF Bank
BIT
LDO
Leonardo
BIT
IVG
Iveco Group NV
BIT
ISP
Intesa Sanpaolo
BIT
RACE
Ferrari NV
BIT
ENI
Eni
BIT
STLAM
Stellantis NV
BIT
NEXI
Nexi S.p.A
BIT
BPE
Bper Banca
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
MB
Mediobanca Banca di Cred...
BIT
BAMI
Banco BPM
BIT
G
Generali
BIT
PRY
Prysmian
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network